
Sign up to save your podcasts
Or


Moderna pops on “robust” early results on its Covid-19 vaccine candidate, but will it pass the next big test? UnitedHealth’s 2nd-quarter profits are much higher than expected, but executives are quick to point out why investors shouldn’t get too excited. Emily Flippen analyzes those stories and shares why she’ll be watching Chinese search giant Baidu this earnings season.
By The Motley Fool4.7
16041,604 ratings
Moderna pops on “robust” early results on its Covid-19 vaccine candidate, but will it pass the next big test? UnitedHealth’s 2nd-quarter profits are much higher than expected, but executives are quick to point out why investors shouldn’t get too excited. Emily Flippen analyzes those stories and shares why she’ll be watching Chinese search giant Baidu this earnings season.

3,217 Listeners

1,482 Listeners

808 Listeners

944 Listeners

521 Listeners

1,170 Listeners

2,201 Listeners

825 Listeners

1,422 Listeners

1,038 Listeners

9,715 Listeners

195 Listeners

833 Listeners

84 Listeners

584 Listeners

1,049 Listeners

56 Listeners